(责任编辑：宋政 HN002) 格隆汇8月1日｜A股市场中药股逆势上涨，其中，生物谷涨近25%，维康药业20CM涨停，新光药业 (300519)涨13%，大唐药业涨近11%，天目药业(600671)、新天药业(002873)、太龙药业(600222)、奇正 藏药(002287)、贵州百灵(002424)10CM涨停，众生药业(002317)涨超8%，亚宝药业(600351)、沃华医药 (002107)涨超6%。 | 代码 | 名称 | 涨幅% ↓ | 总市值 | 年初至今涨幅%。 | | --- | --- | --- | --- | --- | | 833266 | 生物谷 | 24.91 | 17.60亿 | 51.12 | | 300878 | 维康药业 | 20.00 | 37.10亿 | 71.51 | | 300519 | 新光药业 | 13.04 | 31.76亿 | 52.71 | | 836433 | 大唐药业 | 10.76 | 22.14亿 | 42.65 | | 600671 | 天目药业 | 10.03 | 18.71亿 | 74.94 | | 002873 | 新天药业 | 10. ...

MACD金叉信号形成，这些股涨势不错！ 格隆汇8月1日｜A股市场中药股逆势上涨，其中，生物谷（维权）涨近25%，维康药业（维权）20CM 涨停，新光药业涨13%，大唐药业涨近11%，天目药业、新天药业、太龙药业、奇正藏药、贵州百灵 （维权）10CM涨停，众生药业涨超8%，亚宝药业、沃华医药（维权）涨超6%。 | 代码 | 名称 | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | | 833266 | 生物谷 | 24.91 | 17.60亿 | 51.12 | | 300878 | 维康药业 | 20.00 | 37.10亿 | 71.51 | | 300519 | 新光药业 | 13.04 | 31.76 乙 | 52.71 | | 836433 | 大唐药业 | 10.76 | 22.14亿 | 42.65 | | 600671 | 天目药业 | 10.03 | 18.71亿 | 74.94 | | 002873 | 新天药业 | 10.03 | 29.19亿 | 27.68 | | 600222 | 太龙药业 | 10.00 | 39.14 ...

证券时报·数据宝统计，截至今日上午10:29，上证综指3576.84点，收于五日均线之下，涨跌幅0.10%， A股总成交额为7270.04亿元。到目前为止，今日有665只A股价格突破了五日均线，其中乖离率较大的 个股有生物谷、启迪设计、捷佳伟创等，乖离率分别为16.03%、14.73%、12.98%；亿道信息、王子新 材、派克新材等个股乖离率较小，刚刚站上五日均线。 | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 五日均线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 833266 | 生物谷 | 22.10 | 18.16 | 11.95 | 13.87 | 16.03 | | 300500 | 启迪设 计 | 20.00 | 12.63 | 14.02 | 16.08 | 14.73 | | 300724 | 捷佳伟 创 | 20.00 | 16.10 | 58.59 | 66.19 | 12.98 | | 688680 | 海优新 材 | ...

Core Viewpoint - The Chinese medicine sector is experiencing significant growth, with the Zhongzheng Traditional Chinese Medicine Index and related ETFs showing strong performance, indicating a positive market sentiment towards traditional Chinese medicine companies [1][2][3]. Group 1: Market Performance - As of August 1, 2025, the Zhongzheng Traditional Chinese Medicine Index rose by 2.63%, with notable increases in constituent stocks such as Xintian Pharmaceutical (up 10.03%) and Tailong Pharmaceutical (up 10.00%) [1]. - The Zhongzheng Traditional Chinese Medicine ETF (560080) increased by 3.06%, reaching a latest price of 1.15 yuan, and has seen a cumulative increase of 2.58% over the past two weeks [1]. - The trading volume for the Zhongzheng Traditional Chinese Medicine ETF was 59.73 million yuan, with a turnover rate of 3.02% [1]. Group 2: Fund Growth - The Zhongzheng Traditional Chinese Medicine ETF experienced a significant scale increase of 57.84 million yuan over the past week, ranking first among comparable funds [2]. - The ETF's share count grew by 31.50 million shares in the same period, also placing it at the top among comparable funds [3]. Group 3: Capital Flow - The latest net capital outflow for the Zhongzheng Traditional Chinese Medicine ETF was 14.52 million yuan, but there was a net inflow of 43.60 million yuan over the last five trading days, averaging 8.72 million yuan per day [4]. - Leverage funds are increasingly investing in the ETF, with the latest margin buying amounting to 6.77 million yuan and a margin balance of 52.14 million yuan [4]. Group 4: Industry Developments - Tongrentang Group's healthcare segment "Tongrentang Medical Care" successfully listed on the Hong Kong Stock Exchange, marking its fourth company listed in Hong Kong, focusing on integrated medical services [4]. - The company aims to acquire five medical institutions and upgrade systems with the funds raised, projecting revenues between 911 million and 1.175 billion yuan from 2022 to 2024 [4]. Group 5: Regulatory Environment - A nationwide initiative is underway to regulate the pricing of traditional Chinese medicine, addressing issues of inflated prices for commonly used products [5]. - The ongoing centralized procurement of traditional Chinese medicine is expected to expand, affecting 20%-30% of the market, which may lead to increased brand concentration in the retail market [5].

Core Viewpoint - The company has decided to cancel its supervisory board and amend its articles of association to enhance its corporate governance structure, with the supervisory board's responsibilities being transferred to the audit committee of the board [1][2]. Group 1: Board Meeting Details - The 33rd meeting of the 9th Board of Directors was held on July 30, 2025, with all 9 directors present, including some attending via communication [1]. - The meeting's procedures complied with relevant laws and regulations, ensuring the legality and validity of the resolutions made [1]. Group 2: Resolutions Passed - The resolution to cancel the supervisory board and amend the articles of association was passed unanimously with 9 votes in favor, requiring further approval from the shareholders' meeting [2]. - The company also approved the revision of 22 governance documents, including the rules for shareholder meetings and board meetings, with the same unanimous voting outcome [2][3]. - The board approved the nomination of candidates for the 10th Board of Directors, including both non-independent and independent directors, with all resolutions receiving 9 votes in favor [5][6]. Group 3: Upcoming Events - The company plans to hold its third extraordinary shareholders' meeting on August 15, 2025, to review the resolutions passed by the board [6].

General Principles - The company establishes information disclosure regulations to protect investors' rights and comply with relevant laws and regulations [1][2] - Information disclosure is defined as the timely release of information that may significantly impact the company's securities prices [1][2] Basic Principles of Information Disclosure - Information disclosure is a continuous responsibility of the company, requiring timely, truthful, accurate, and complete information [2][3] - Information must be disclosed simultaneously to all investors, and insider information must not be leaked before official disclosure [2][3] Content and Standards of Information Disclosure - The company must disclose periodic reports, temporary reports, and other relevant documents as required by law [5][6] - Annual reports must be disclosed within four months after the fiscal year-end, and interim reports within two months after the first half of the fiscal year [6][7] Procedures for Information Disclosure - The company must follow specific procedures for preparing, reviewing, and disclosing periodic reports, ensuring that all necessary approvals are obtained [12][13] - Major events that could significantly affect the company's securities must be disclosed immediately [9][10] Responsibilities of Information Disclosure Personnel - The board secretary is responsible for managing information disclosure and ensuring compliance with regulations [14][15] - Directors and senior management must cooperate with the board secretary and ensure timely and accurate information reporting [16][17] Confidentiality Measures - Company personnel with access to undisclosed information must maintain confidentiality and not misuse insider information [19][20] - The company should implement necessary measures to limit the number of individuals who have access to sensitive information [19][20] Accountability and Penalties - Directors and senior management are accountable for the truthfulness, accuracy, completeness, and timeliness of disclosed information [21][22] - Violations of disclosure regulations may result in penalties imposed by the board of directors based on the severity of the breach [21][22]

Core Viewpoint - The document outlines the establishment of a compensation and assessment management system for the board of directors and senior management of Henan Tailong Pharmaceutical Co., Ltd, aiming to enhance corporate governance and comply with relevant laws and regulations [1][2]. Group 1: Committee Structure - The Compensation and Assessment Committee is a specialized committee under the board of directors, responsible for formulating assessment standards and compensation policies for directors and senior management [1]. - The committee consists of three directors, with a majority being independent directors, and is chaired by an independent director [4][5]. - The term of the committee aligns with that of the board, and members can be re-elected upon term expiration [4] Group 2: Responsibilities and Authority - The main responsibilities of the committee include developing assessment standards, reviewing compensation policies, and making recommendations to the board on various matters [3]. - Compensation plans for directors must be approved by the board and submitted for shareholder approval, while plans for senior management require board approval [3][5]. - The board must document and disclose any reasons for not adopting the committee's recommendations [3][5]. Group 3: Meeting Procedures - The committee is required to hold at least one regular meeting annually, with provisions for additional meetings as necessary [4]. - Meetings can be conducted in person or via teleconference, ensuring all members can communicate effectively [4][5]. - A quorum of two-thirds of the committee members is required for meetings, and decisions must be made by a majority vote [5][6]. Group 4: Documentation and Confidentiality - Meeting records must be created and signed by attendees, with a retention period of no less than ten years [5]. - All participants in the meetings are bound by confidentiality regarding the discussed matters [5][6].

Core Points - The document outlines the governance structure and operational guidelines for Henan Tailong Pharmaceutical Co., Ltd, focusing on the roles and responsibilities of the general manager and other key management positions [1][2][3]. Group 1: General Manager's Role - The company appoints one general manager, who is responsible for the overall management and implementation of the board's resolutions [1]. - The general manager has a three-year term and can be reappointed [1]. - Responsibilities include organizing production management, implementing annual plans, and proposing internal management structures [1][3]. Group 2: Deputy General Manager's Responsibilities - The deputy general manager is accountable for business management within their scope and must report regularly to the general manager [2]. - They are responsible for executing tasks assigned by the general manager and the board [2]. Group 3: Financial Officer's Duties - The financial officer oversees the financial department and is responsible for internal controls and audits [2]. - They must review financial reports and ensure compliance with accounting standards [2]. Group 4: Board Secretary's Functions - The board secretary is tasked with preparing and managing shareholder and board meetings, as well as handling information disclosure [2]. Group 5: General Manager's Responsibilities - The general manager must maintain shareholder interests and ensure effective implementation of the board's plans [3]. - They are also responsible for enhancing management levels and economic efficiency [3]. - Regular reporting to the board and adherence to company regulations are mandatory [4]. Group 6: Meeting Procedures - The general manager's office meetings are held weekly to discuss significant operational matters [4]. - Decisions made in these meetings must be executed by relevant departments and reported back to the general manager [4]. Group 7: Miscellaneous Provisions - The document stipulates that any unresolved issues will be governed by relevant laws and the company's articles of association [5]. - The guidelines take effect upon approval by the board [5].

第四条 独立董事应当独立履行职责，不受公司及公司主要股东、 实际控制人以及其他与公司存在利害关系的组织或者个人的影响。公 司应当为独立董事依法履职提供必要保障。 第五条 公司独立董事占董事会成员的比例不得低于三分之一， 且至少包括一名会计专业人士。公司董事会审计委员会中独立董事 应当过半数，并由独立董事中会计专业人士担任召集人；提名委员 会、薪酬与考核委员会中独立董事应当过半数并担任召集人。 河南太龙药业股份有限公司 第一章 总 则 第一条 河南太龙药业股份有限公司（以下简称"公司"）为进 一步完善法人治理结构，促进公司持续规范发展，为独立董事创造良 好的工作环境，充分发挥独立董事在公司治理中的作用，根据《中华 人民共和国公司法》《中华人民共和国证券法》《上市公司独立董事 管理办法》《上海证券交易所上市公司自律监管指引第1号——规范 运作》等有关法律法规以及《河南太龙药业股份有限公司章程》（以 下简称"《公司章程》"）的规定，制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与 公司及公司主要股东、实际控制人不存在直接或者间接利害关系，或 者其他可能影响其进行独立客观判断关系的董事。 第三条 ...

河南太龙药业股份有限公司 第一章 总 则 第一条 河南太龙药业股份有限公司（以下简称"公司"）为进 一步完善法人治理结构，充分发挥独立董事参与决策、监督制衡、专 业咨询的作用，维护公司整体利益，保护中小股东合法权益，根据中 国证券监督管理委员会《上市公司独立董事管理办法》、上海证券交 易所《上市公司自律监管指引第1号——规范运作》以及《河南太龙 药业股份有限公司章程》（以下简称"《公司章程》"）《独立董事 工作制度》等相关规定，特制定本细则。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与 公司及其主要股东、实际控制人不存在直接或间接利害关系，或者其 他可能影响其进行独立客观判断关系的董事。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当 认真履行职责，在董事会中发挥参与决策、监督制衡、专业咨询作用， 维护公司整体利益，保护中小股东合法权益。 第四条 独立董事专门会议是指全部由公司独立董事参加的会 议。 第二章 职责权限 第五条 下列事项应当经公司独立董事专门会议审议，并经全体 独立董事过半数同意后，提交董事会审议： （二）向董事会提议召开临时股东会； （三）提议召开董事会会议。 独立董事 ...